These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

664 related items for PubMed ID: 21317409

  • 1. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
    Capone D, Tarantino G, Kadilli I, Polichetti G, Basile V, Federico S, Sabbatini M.
    Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409
    [Abstract] [Full Text] [Related]

  • 2. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 3. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
    Pawinski T, Luszczynska P, Durlik M, Majchrzak J, Baczkowska T, Chrzanowska M, Sobiak J, Glyda M, Kuriata-Kordek M, Kamińska D, Krajewska M, Klinger M.
    Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
    [Abstract] [Full Text] [Related]

  • 4. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, van Gelder T, Cattaneo D.
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
    Xu L, Cai M, Shi BY, Li ZL, Li X, Jin HL.
    Transplant Proc; 2014 Jun; 46(5):1362-5. PubMed ID: 24935300
    [Abstract] [Full Text] [Related]

  • 7. A possible simplification for the estimation of area under the curve (AUC₀₋₁₂) of enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.
    Fleming DH, Mathew BS, Prasanna S, Annapandian VM, John GT.
    Ther Drug Monit; 2011 Apr; 33(2):165-70. PubMed ID: 21383656
    [Abstract] [Full Text] [Related]

  • 8. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K, Glander P, Krämer BK, Fischer W, Hoffmann U, Bauer S, Grohmann J, Neumayer HH, Arns W.
    Transplantation; 2007 Feb 27; 83(4):417-24. PubMed ID: 17318074
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.
    Hummel M, Yonan N, Ross H, Miller LW, Sechaud R, Balez S, Koelle EU, Gerosa G, ERL 2401 Study Group.
    Clin Transplant; 2007 Feb 27; 21(1):18-23. PubMed ID: 17302587
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
    Langone A, Shihab F, Pankewycz O, Doria C, Wiland A, McCague K, Chan L.
    Clin Transplant; 2014 Sep 27; 28(9):961-7. PubMed ID: 24893821
    [Abstract] [Full Text] [Related]

  • 15. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb 27; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 16. Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients.
    Cattaneo D, Merlini S, Baldelli S, Bartolini B, Nicastri A, Gotti E, Remuzzi G, Perico N.
    Ther Drug Monit; 2006 Oct 27; 28(5):643-9. PubMed ID: 17038879
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
    Huang HF, Yao X, Chen Y, Xie WQ, Shen-Tu JZ, Chen JH.
    Int J Clin Pract Suppl; 2014 Apr 27; (181):4-9. PubMed ID: 24673713
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.